Wordt geladen...
Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment. This retrospective cohort included patients hospitalized for a major bleed that result...
Bewaard in:
| Gepubliceerd in: | Clin Appl Thromb Hemost |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7019392/ https://ncbi.nlm.nih.gov/pubmed/31876159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029619896619 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|